Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1-Reference-Cited by-同舟云学术

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

Published:2020-11-01 Issue:6 Volume:21 Page:151-167
ISSN:2578-7489
Container-title:HIV Research & Clinical Practice
language:en
Short-container-title:HIV Research & Clinical Practice

Author:

Huhn Gregory D.¹,Wilkin Aimee²,Mussini Cristina³,Spinner Christoph D.⁴^ORCID,Jezorwski John⁵,El Ghazi Mohsine⁶,Van Landuyt Erika⁶,Lathouwers Erkki⁶,Brown Kimberley⁶,Baugh Bryan⁷,

Affiliation:

1. Ruth M. Rothstein CORE Center, Chicago, IL, USA

2. Section on Infectious Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA

3. Department of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy

4. School of Medicine, Technical University of Munich, Munich, Germany

5. Janssen Research and Development LLC, Pennington, NJ, USA

6. Janssen Pharmaceutica NV, Beerse, Belgium

7. Janssen Research and Development LLC, Raritan, NJ, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/25787489.2020.1844520

Reference60 articles.

1. HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts

2. Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era

3. Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens

4. SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets Summary of Product Characteristics. Janssen-Cilag International NV. https://www.medicines.org.uk/emc/product/8430. Published 2017. Revised July 2019. Accessed October 19, 2020.

5. Prescribing information for SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets. Janssen Pharmaceutical Companies. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SYMTUZA-pi.pdf. Published 2018. Revised March 2020. Accessed October 19, 2020.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiometabolic health in people with HIV: expert consensus review;Journal of Antimicrobial Chemotherapy;2024-04-24

2. A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults;Expert Review of Anti-infective Therapy;2023-10-10

3. A Combination of Novel HIV-1 Protease Inhibitor and Cytochrome P450 (CYP) Enzyme Inhibitor to Explore the Future Prospective of Antiviral Agents: Evotaz;Current HIV Research;2023-09-05

4. HIV Preintegration Transcription and Host Antagonism;Current HIV Research;2023-09-05

5. Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B;Experimental and Therapeutic Medicine;2021-09-20